BGI Genomics Co., Ltd. (SHE: 300676)
China
· Delayed Price · Currency is CNY
35.56
+0.76 (2.18%)
Sep 9, 2024, 1:43 PM CST
BGI Genomics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Net Income | 61.31 | 92.9 | 802.77 | 1,462 | 2,090 | 276.33 | Upgrade
|
Depreciation & Amortization | 426.71 | 418.75 | 453.07 | 370.6 | 302.33 | 241.08 | Upgrade
|
Other Amortization | 70.17 | 54.24 | 34.61 | 25.82 | 25.89 | 22.74 | Upgrade
|
Loss (Gain) From Sale of Assets | -3.59 | -2.76 | -0.11 | 3.88 | 4.23 | -2.69 | Upgrade
|
Asset Writedown & Restructuring Costs | 67.46 | 20.5 | 209.24 | 102.24 | 105.02 | 102.55 | Upgrade
|
Loss (Gain) From Sale of Investments | 45.43 | 33.07 | -388.21 | -260.29 | -153.32 | -18.53 | Upgrade
|
Provision & Write-off of Bad Debts | 66.41 | 66.41 | 185.1 | 104.56 | 140.86 | - | Upgrade
|
Other Operating Activities | 93.09 | 82.53 | 325.54 | 130.7 | 131.05 | 0.05 | Upgrade
|
Change in Accounts Receivable | -109.32 | 736.49 | -1,086 | 254.15 | -471.96 | -421.61 | Upgrade
|
Change in Inventory | -12.37 | 103.78 | 46.25 | 169.94 | -603.7 | -101.07 | Upgrade
|
Change in Accounts Payable | -528.88 | -1,345 | -484.64 | 147.51 | 2,117 | 107.97 | Upgrade
|
Change in Other Net Operating Assets | 122.81 | 122.81 | 22.85 | - | - | - | Upgrade
|
Operating Cash Flow | 325.97 | 408.77 | 130.88 | 2,476 | 3,603 | 224.25 | Upgrade
|
Operating Cash Flow Growth | -9.07% | 212.31% | -94.71% | -31.27% | 1506.52% | 1426.86% | Upgrade
|
Capital Expenditures | -909.94 | -1,236 | -1,267 | -383.52 | -301.15 | -626.44 | Upgrade
|
Sale of Property, Plant & Equipment | 6.94 | 2.72 | 0.33 | 0.71 | 4.04 | 1.3 | Upgrade
|
Cash Acquisitions | - | - | 5.2 | - | - | - | Upgrade
|
Divestitures | - | - | -0.01 | 5.91 | - | - | Upgrade
|
Investment in Securities | -926.1 | -763.71 | 569.72 | -2,069 | 431.01 | -263.03 | Upgrade
|
Other Investing Activities | 89.48 | 246.64 | 111.31 | 153.44 | 60.08 | 45.51 | Upgrade
|
Investing Cash Flow | -1,740 | -1,751 | -580.07 | -2,292 | 193.98 | -842.67 | Upgrade
|
Long-Term Debt Issued | - | 251.68 | 20 | 5 | 1,289 | - | Upgrade
|
Total Debt Issued | 214.77 | 251.68 | 20 | 5 | 1,289 | - | Upgrade
|
Long-Term Debt Repaid | - | -78.77 | -780.21 | -690.2 | -60.42 | - | Upgrade
|
Total Debt Repaid | -86.22 | -78.77 | -780.21 | -690.2 | -60.42 | - | Upgrade
|
Net Debt Issued (Repaid) | 128.55 | 172.91 | -760.21 | -685.2 | 1,228 | - | Upgrade
|
Issuance of Common Stock | - | 5 | - | 2,003 | - | - | Upgrade
|
Repurchase of Common Stock | -384.95 | - | -336.74 | - | -482.32 | - | Upgrade
|
Common Dividends Paid | -6.18 | -416.73 | -167.13 | -177.78 | -62.29 | -40.01 | Upgrade
|
Other Financing Activities | -31.24 | -28.05 | 69.54 | -102.79 | 466.78 | 388.02 | Upgrade
|
Financing Cash Flow | -293.82 | -266.88 | -1,195 | 1,037 | 1,150 | 348.01 | Upgrade
|
Foreign Exchange Rate Adjustments | -45.85 | 32.82 | 279.38 | -139.91 | -262.52 | 5.21 | Upgrade
|
Net Cash Flow | -1,753 | -1,576 | -1,364 | 1,081 | 4,685 | -265.19 | Upgrade
|
Free Cash Flow | -583.97 | -827.62 | -1,136 | 2,093 | 3,302 | -402.18 | Upgrade
|
Free Cash Flow Growth | - | - | - | -36.62% | - | - | Upgrade
|
Free Cash Flow Margin | -14.07% | -19.03% | -16.10% | 30.93% | 39.32% | -14.36% | Upgrade
|
Free Cash Flow Per Share | -1.40 | -2.01 | -2.77 | 5.08 | 8.27 | -1.01 | Upgrade
|
Cash Income Tax Paid | 165.52 | 144.8 | 336.02 | 419.82 | 490.87 | 97.06 | Upgrade
|
Levered Free Cash Flow | -850.01 | -379.34 | -619.14 | 1,633 | 2,799 | 210.83 | Upgrade
|
Unlevered Free Cash Flow | -796.68 | -322.12 | -556.16 | 1,698 | 2,855 | 214.42 | Upgrade
|
Change in Net Working Capital | 618.17 | -247.89 | 343 | -635.08 | -1,080 | -416.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.